Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.

AUTOR(ES)

Kovacs, J A

RESUMO

Piritrexim, a lipid-soluble antifolate, was evaluated for its activity against Pneumocystis carinii and Toxoplasma gondii. The concentration of piritrexim needed to inhibit 50% of the catalytic activity of P. carinii dihydrofolate reductase (DHFR) was 19.3 nM, and that for T. gondii DHFR was 17.0 nM, concentrations that were 40- to over 1,000-fold less than those needed for the inhibition of activity by trimethoprim and pyrimethamine, the antifolates conventionally used in treating these organisms. Piritrexim was able to inhibit replication of T. gondii in a mouse peritoneal macrophage model at concentrations of 0.1 to 1.0 microM. Leucovorin, a reduced folate that can bypass the inhibition of DHFR by antifols in mammalian cells but not in protozoa, did not affect the ability of piritrexim to inhibit T. gondii replication. The addition of sulfadiazine, which alone was ineffective, to piritrexim allowed inhibition of T. gondii replication at lower concentrations of piritrexim than when piritrexim was used alone. These results suggest that piritrexim, alone or combined with a sulfonamide, may be a highly potent antitoxoplasma and antipneumocystis agent that could provide major pharmacologic and clinical advantages over available agents.

Documentos Relacionados

• Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.
• Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations.
• Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.
• Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells
• DIURNAL VARIATION IN THE URINARY EXCRETION OF NEUTRAL LIPID-SOLUBLE REDUCING STEROIDS IN CONGESTIVE CARDIAC FAILURE AND CIRRHOSIS OF THE LIVER WITH ASCITES 12